Drug intelligence / Profile preview

Calcisome-D

Development stage: Unknown
Lead developer: Orchidia Pharma
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

Calcisome-D is an oral nutritional supplement developed by Orchidia Pharmaceutical Industries. It is formulated as a combination of calcium, vitamin D3, and vitamin K2, utilizing liposomal technology to enhance the absorption and bioavailability of these nutrients. The supplement is designed to support bone and dental health by ensuring efficient calcium delivery to the skeletal system while minimizing potential side effects associated with improper calcium deposition. Vitamin K2 specifically aids in directing calcium to the bones rather than soft tissues, while Vitamin D3 facilitates intestinal calcium absorption.

Brand names: Calcisome-D

Targets

GGCX (Vitamin K-dependent gamma-glutamyl carboxylase)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Calcisome-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcisome-D.

Explore the full profile